- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | bluebird bio Bolsters Management Team with Appointments | ||
| Di | Frontage Expands Business in Canada with New Leadership | ||
| Di | BioMarin Completes Acquisition of Inozyme Pharma for $270M | ||
| Di | Merck KGaA, Darmstadt, Germany Acquires SpringWorks Therapeutics for $3.4M | ||
| Di | Fresenius Expands Biosimilars Portfolio with Denosumab Biosimilars in the U.S. | ||
| Mo | AAPS Reveals Opening & Closing Plenary Speakers for 2025 PharmSci 360 | ||
| Mo | Particle Dynamics Acquires EUROAPI UK | ||
| Mo | UI Pharmaceuticals Partners with MimiVax for Glioblastoma Vaccine | ||
| Mo | Keystone Folding Box Co., Med-Con Technologies Partner to Enhance Key-Pak | ||
| Mo | Piramal Pharma Solutions Breaks Ground on New Expansion | ||
| Mo | Veranova Appoints Dr. Matteo Villain as VP of Peptides & Oligonucleotides | ||
| Mo | ProFound Therapeutics Inks $70M+ Deal with Novartis | ||
| Mo | FDA Approves Takeda's Gammagard Liquid ERC | ||
| Mo | Mabion, NovalGen Partner to Bring NVG-222 to Market | ||
| Mo | Circio, NeoRegen Biotech to Advance Circular RNA Delivery Collaboration | ||
| Mo | Hikma Pharmaceuticals to Invest $1B in U.S. Manufacturing & R&D Capabilities | ||
| Fr | Vetter Breaks Ground on Des Plaines Manufacturing Site | ||
| Fr | FDA Approves REMS Programs in BMS Cell Therapy Labels | ||
| Fr | PrioBio Opens Flagship Cell & Gene Therapy Center of Excellence in Hopewell, NJ | ||
| Do | GenSight Transfers Upstream Phase of LUMEVOQ Manufacturing Process to Catalent | ||
| Do | Incyte Appoints Bill Meury Chief Executive Officer | ||
| Do | AGC Biologics Expands Cell Therapy Development Operations to Asia | ||
| 25.06. | MAIA Biotechnology, Roche Partner for Hard-to-Treat Cancer Therapies | ||
| 25.06. | Silo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment | ||
| 25.06. | Bio-Thera & SteinCares Ink Dupilumab Biosimilar Deal for Latin America |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .